Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
Gerwin D. Rodenburg1 , Sabine C. de Greeff1, Angelique G.C.S. Jansen, Hester E. de Melker, Leo M. Schouls, Eelko Hak, Lodewijk Spanjaard, Elisabeth A.M. Sanders2, and Arie van der Ende2
Author affiliations: Wilhelmina Children’s Hospital/University Medical Center, Utrecht, the Netherlands (G.D. Rodenburg, A.G.C.S Jansen, E. Hak, E.A.M. Sanders); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, H.E. de Melker, L.M. Schouls); University Medical Center, Groningen, the Netherlands (E. Hak); Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands (L. Spanjaard, A. van der Ende); 1, 2These pairs of authors contributed equally to this study.
Figure 5. Age group–specific theoretical coverage of pneumococcal conjugate vaccines during the preimplementation and postimplementation periods of 7-valent pneumococcal conjugate vaccine (PCV-7), the Netherlands. IPD, invasive pneumococcal disease; PCV-10/PCV13, additional coverage by PCV-10 and PCV-13; PCV-13, additional coverage by PCV-13 alone; pre, preimplementation period (June 2004–June 2006); post, postimplementation period (June 2006–June 2008).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.